HCPCS code G0481: Drug test, definitive, 8-14 drug classes, per day

Properly code and bill for HCPCS code G0481 by meeting the documentation and billing requirements in this short guide.

## **What is HCPCS code G0481?** HCPCS code G0481 is for definitive (quantitative/confirmatory) drug testing that identifies 8 to 14 drug classes, including metabolites. This service uses highly specific drug identification methods, such as GC/MS or LC/MS, to accurately identify individual drugs and distinguish structural isomers, making it far more detailed than a simple screen. The primary purpose of this service is to monitor patient compliance in substance use disorder treatment or chronic pain management programs, confirm unexpected results from presumptive screening, or identify the specific concentration of a substance to guide a patient's treatment plan. The code is reported only once per patient per day and is inclusive of specimen validity testing.

## **G0481 documentation requirements** To ensure proper reimbursement for HCPCS code G0481, healthcare providers must adhere to specific documentation standards: ### **Written order** A signed, valid requisition form or order from the treating provider that specifies the drugs or drug classes to be tested. "Custom" or non-specific panels are often not reimbursable unless all components are individually medically necessary. ### **Medical necessity rationale** Documentation (e.g., progress notes, history and physical) by the ordering/treating provider demonstrating why the definitive test is necessary, which may include: - Monitoring compliance with a chronic pain or substance use disorder treatment plan. - A presumptive drug screen result that is inconsistent with the patient's self-report, presentation, medical history, or current prescriptions. - The need to identify a specific drug, metabolite, or definitive concentration to guide treatment. - Assessment when clinical evaluation suggests the use of non-prescribed medications or illegal substances. ### **Specific details** The requisition form and/or medical record should include: - Complete list of the drug class(es) being tested. - Patient and provider identification (including NPI). - Date and time the sample was collected/received. - Primary diagnosis and appropriate ICD-10 code(s). ### **Test results** Complete results of the definitive tests performed, which should be maintained by the rendering provider if different from the ordering provider. Maintaining comprehensive records ensures compliance with Medicare and other insurance requirements, facilitating smooth reimbursement processes.

## **G0481 billing requirements** When billing for HCPCS code G0481, providers should adhere to the following guidelines: - **Units of service**: G0481 is a per-day service. It should be reported once per patient per day, regardless of the number of individual drug classes (within the 8-14 range) or procedures performed. - **Inclusion of specimen validity testing**: Specimen validity testing is explicitly included in the code and cannot be billed separately. - **Modifier**: Some payers, including certain Medicare Administrative Contractors, may require the KX modifier on definitive drug testing codes (G0480-G0483) to certify that documentation supports medical necessity. - **Frequency limits**: Coverage policies often place limits on the frequency of definitive testing. Adhering to these billing requirements helps prevent claim denials and ensures timely reimbursement.

## **Other relevant codes** - **G0480**: Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed - **G0482**: Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed - **G0483**: Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed**Bold** - **G0659**: Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem), excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (e.g., alcohol dehydrogenase), performed without method or drug-specific calibration, without matrix-matched quality control material, or without use of stable isotope or other universally recognized internal standard(s) for each drug, drug metabolite or drug class per specimen; qualitative or quantitative, all sources, includes specimen validity testing, per day, any number of drug classes

Frequently asked questions

Generally, yes, if both are medically necessary on the same date of service. Definitive testing is often necessary to confirm or clarify unexpected results from an initial presumptive screen. However, some payers may limit the total number of combined tests.

No. The code description specifically states "per day," meaning you report it once, regardless of how many individual tests within the 8-14 drug class range are performed.

G0481 should only be used when the definitive test performed actually covered 8 to 14 drug classes, and medical necessity supports testing for that many classes. Many coverage policies emphasize that definitive testing for more than seven drug classes (G0481, G0482, G0483) is only appropriate in rare, clinically justified circumstances.